Ann: Application for quotation of securities - PAA, page-46

How do you think this conversation will go with HEALEY ALS platform (USA) & TRICALS (EU), [any other interested major player]

Yes I know we received Orphan Drug Designation and our results are stunning plus the data package continues to grow with our long living open label extension study participants.

The thing is, were just a tad short on cash so we are going to fish around other avenues to fill the funding gaps and we should be re-engaging in about a year or two.

I DON'T THINK SO....

Reality - these organisations have (conservatively) literally spent hundreds of millions of $USD$ searching for a drug that can do what MONEPANTEL is doing!!

You don't think these guys are connected to Major Pharma? If ODD isn't enough to get major Pharma's attention, I would think these folks would help open doors to avoid any delays.

Couple this with the devastating happenings for Relyvrio putting ALS/MND on the front pages for all the wrong reasons, one would have to think that PharmAust and MPL are already becoming eye candy for M&A teams.

Adreamer